IL-5 and eosinophilia

Current Opinion in Immunology

Volumn 20, Issue 3, 2008, Pages 288-294

  Takatsu, Kiyoshi ^a   Nakajima, Hiroshi ^b  

^a UNIVERSITY OF TOYAMA   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CHEMOKINE RECEPTOR CCR3; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; JANUS KINASE; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KM1259; MONOCLONAL ANTIBODY MEDI 563; OCTAMER TRANSCRIPTION FACTOR 2; RESLIZUMAB; STAT PROTEIN;

ABSENCE OF SIDE EFFECTS; ASTHMA; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; GENE CONTROL; HUMAN; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; EOSINOPHILIA; EOSINOPHILS; HUMANS; INTERLEUKIN-5; MICE; RECEPTORS, INTERLEUKIN-5; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 45449096652     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2008.04.001     Document Type: Review

References (64)

1. Takatsu K, Dickason R, Huston D: Interleukin-5. In Growth Factors and Cytokines in Health and Disease. Volume IIA, edited by LeRoith D, Bondy C, JAI Press Inc., London. 1997: 143-200.
2. Takatsu K., Takaki S., and Hitoshi Y. Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv Immunol 57 (1994) 145-190
3. Moon B.G., Yoshida T., Shiiba M., Nakao K., Katsuki M., Takaki S., and Takatsu K. Functional dissection of the cytoplasmic subregions of the interleukin-5 receptor alpha chain in growth and immunoglobulin G1 switch recombination of B cells. Immunology 102 (2001) 289-300
4. Takatsu K. Interleukin 5 and B cell differentiation. Cytokines Growth Factor Rev 9 (1998) 25-35
5. + B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4 (1996) 15-24
6. Yoshida T., Ikuta K., Sugaya H., Maki K., Takagi M., Kanazawa H., Sunaga S., Kinashi T., Yoshimura K., Miyazaki J., et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5Rα-deficient mice. Immunity 4 (1996) 483-494
7. Hiroi T., Yanagita M., Iijima H., Iwatani K., Yoshida T., Takatsu K., and Kiyono H. Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgAproducing B-1 cell in mucosa-associated tissues. J Immunol 162 (1999) 821-828
8. Moon B.-Y., Miyake K., Takaki S., and Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol 172 (2004) 6020-6029
9. Horikawa K., Kaku H., Nakajima H., Davey H.W., Hennighausen L., Iwamoto I., Yasue T., Kariyone A., and Takatsu K. Essential role of Stat5 for IL-5-dependent IgH switch recombination in mouse B cells. J Immunol 167 (2001) 5018-5026
10. Shapiro-Shelef M., Lin K.I., McHeyzer-Williams L.J., Liao J., McHeyzer-Williams M.G., and Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19 (2003) 607-620
11. Kay A.B. Allergy and allergic diseases. First of two parts. N Eng J Med 344 (2001) 30-37
12. Cohn L., Elias J.A., and Chupp G.L. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 22 (2004) 789-815
13. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 17 (1999) 255-281
14. O'Garra A., and Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol 10 (2000) 542-550
15. Murphy K.M., and Reiner S.L. The lineage decisions of helper T cells. Nat Rev Immunol 2 (2002) 933-944
16. Nakajima H., and Takatsu K. Role of cytokines in allergic inflammation. Int Archives Allergy Immunol 142 (2007) 265-273
17. Asquith K.L., Ramshaw H.S., Hansbro P.M., Beagley K.W., Lopez A.F., and Foster P.S. The IL-3/IL-5/GM-CSF common β receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation. J Immunol 180 (2008) 1199-1206
18. Warren H.S., Kinnear B.F., Phillips J.H., and Lanier L.L. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol 154 (1995) 5144-5152
19. Desreumaux P., Janin A., Colombel J.F., Prin L., Plumas J., Emilie D., Torpier G., Capron A., and Capron M. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 175 (1992) 293-296
20. Sakuishi K., Oki S., Araki M., Porcelli S.A., Miyake S., and Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 179 (2007) 3452-3462. This is a report describing iNKT cell subset producing IL-5 and IL-13 that nay play a major role in the development of allergic disease or asthma and also in the immune regulation of Th1 inflammation.
21. + Peyer's patch cells are a novel cell subset which secrete IL-5 in response to IL-2 and implicate for their role in IgA production.
22. Kikuchi Y., Yasue T., Miyake K., Kimoto M., and Takatsu K. CD38 ligation induces tyrosine phosphorylation of Bruton tyrosine kinase and enhanced expression of interleukin 5-receptor alpha chain: synergistic effects with interleukin 5. Proc Natl Acad Sci U S A 92 (1995) 11814-11818
23. Emslie D., D'Costa K., Hasbold J., Metcalf D., Takatsu K., Hodgkin P.O., and Corcoran L.M. Oct2 enhances antibody secreting cell differentiation through regulation of IL-5 receptor alpha chain expression on activated B cell. J Exp Med 205 (2008) 409-421
24. Sato S., Katagiri T., Takaki S., Kikuchi Y., Hitoshi Y., Yonehara S., Tsukada S., Kitamura D., Watanabe T., Witte O.N., et al. IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J Exp Med 180 (1994) 2101-2110
25. Kikuchi Y., Hirano M., Seto M., and Takatsu K. Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology-domain of mouse Btk. Int Immunol 12 (2000) 1397-1408
26. Hirano M., Kikuchi Y., Nisitani S., Yamaguchi A., Sato A., Ito T., Iba H., and Takatsu K. Bruton's tyrosine kinase (Btk) enhances transcriptional co-activation activity of BAM11, a Btk-associated molecule of a subunit of SWI/SNF complexes. Int Immunol 16 (2004) 747-757
27. Horikawa K., and Takatsu K. Interleukin-5 regulates genes involved in B cell terminal maturation. Immunology 118 (2006) 497-508
28. Ogata N., Kouro T., Yamada A., Koike M., Hanai N., Ishikawa T., and Takatsu K. JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5) receptor α and βc subunit, respectively, and are activated upon IL-5 stimulation. Blood 91 (1998) 2264-2271
29. Kagami S., Nakajima H., Kumano K., Suzuki K., Suto A., Imada K., Davey H.W., Saito Y., Takatsu K., Leonard W.J., et al. Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue. Blood 95 (2000) 1370-1377
30. Coffer P.J., Schweizer R.C., Dubois G.R., Maikoe T., Lammers J.W., and Koenderman L. Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and the T-helper 2-derived cytokines interleukin-4 and interleukin-5. Blood 91 (1998) 2547-2557
31. Pazdrak K., Schreiber D., Forsythe P., Justement L., and Alam R. The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med 181 (1995) 1827-1834
32. Hall D.J., Cui J., Bates M.E., Stout B.A., Koenderman L., Coffer P.J., and Bertics P.J. Transduction of a dominant-negative H-Ras into human eosinophils attenuates extracellular signal-regulated kinase activation and interleukin-5-mediated cell viability. Blood 98 (2001) 2014-2021
33. Pazdrak K., Olszewska-Pazdrak B., Stafford S., Garofalo R.P., and Alam R. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 188 (1998) 421-429
34. Martinez-Moczygemba M., Huston D.P., and Lei J.T. JAK kinases control IL-5 receptor ubiquitination, degradation and internalization. J Leuk Biol 81 (2007) 1137-1148
35. Martinez-Moczygemba M., and Huston D.P. Proteasome regulation of βc signaling reveals a novel mechanism for heterotypic desensitization. J Clin Invest 108 (2001) 1797-1806
36. Wakioka T., Sasaki A., Kato R., Shouda T., Matsumoto A., Miyoshi K., Tsuneoka M., Komiya S., Baron R., and Yoshimura A. Spred is a Sprouty-related suppressor of Ras signalling. Nature 412 (2001) 647-651
37. Inoue H., Kato R., Fukuyama S., Nonami A., Taniguchi K., Matsumoto K., Nakano T., Tsuda M., Matsumura M., Kubo M., et al. Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J Exp Med 201 (2005) 73-82. The Sprouty-related Ena/VASP homology 1-domaincontaining protein (Spred)-1 is a negative regulator of growth factor-mediated, Ras-dependent ERK activation. By using Spred-1-deficient mice, authors demonstrated that Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness, without affecting helper T cell differentiation.
38. Iwasaki H., Mizuno S., Mayfield R., Shigematsu H., Arinobu Y., Seed B., Gurish M.F., Takatsu K., and Akashi K. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 201 (2005) 1891-1897
39. lo eosinophil progenitor cells (EoPs) in the normal bone marrow give rise exclusively to eosinophils. EoPs significantly increase in number in response to helminth infection, suggesting that the EoP stage is physiologically involved in eosinophil production in vivo. Authors also demonstrated that the expression of GATA-2 instructs C/EBPα-expressing GMPs to commit exclusively into the eosinophil lineage, while it induces basophil and/or mast cell lineage commitment if C/EBPα is suppressed at the GMP stage. They propose that the order of expression of key transcription factors is critical for their interplay to selectively drive lineage specification programs.
40. Hamelmann E., and Gelfand E.W. IL-5-induced airway eosinophilia-the key to asthma?. Immunol Rev 179 (2001) 182-191
41. Kay A.B. The role of eosinophils in the pathogenesis of asthma. Trends Mol Med 11 (2005) 148-152
42. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
43. + T-lymphocytes and interleukin-5 mediate antigen-induced eosinophil infiltration into the mouse trachea. Am Rev Respir Dis 146 (1992) 374-377
44. Akutsu I., Kojima T., Kariyone A., Fukuda T., Makino S., and Takatsu K. Antibody against interleukin-5 prevents antigen-induced eosinophil infiltration and bronchial hyper- reactivity in the guinea pig airways. Immunol Lett 45 (1995) 109-116
45. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., and Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 183 (1996) 195-201
46. Tanaka H., Kawada N., Yamada T., Kawada K., Takatsu K., and Nagai H. Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor α chain-deficient mice. Clin Exp Allergy 30 (2000) 874-881
47. Bousquet J., Chanez P., Lacoste J.Y., Barnéon G., Ghavanian N., Enander I., Venge P., Ahlstedt S., Simony-Lafontaine J., Godard P., et al. Eosinophilic inflammation in asthma. N Engl J Med 323 (1990) 1033-1039
48. Robinson D.S., Hamid Q., Ying S., Tsicopoulos A., Barkans J., Bentley A.M., Corrigan C., Durham S.R., and Kay A.B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 326 (1992) 298-304
49. Shi H., Qin S., Huang G., Chen Y., Xiao C., Xu H., Liang G., Xie Z., Qin X., Wu J., et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol 16 (1997) 220-224
50. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., Mathur A.K., Cowley H.C., Chung K.F., Djukanovic R., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
51. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A., Postma D.S., Danzig M., Cuss F., and Pauwels R.A. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167 (2003) 1655-1659
52. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., Robinson D., Wenzel S., Busse W., Hansel T.T., et al., International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007) 1062-1071. In this study, the effect of mepolizumab on patients with moderate persistent asthma was evaluated by multicenter, randomized, double-blind, placebo-controlled study. While the administration of mepolizumab was associated with a significant reduction in blood and sputum eosinophils, there were no statistically significant changes in any of the clinical end points including morning peak expiratory flow, daily β2-agonist use, symptom scores, exacerbation rates, and quality of life measures.
53. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., Jarjour N.N., Busse W.W., and Kelly E.A. Decreased expression of membrane IL-5 receptor α on human eosinophils: I. Loss of membrane IL-5 receptor α on airway eosinophils and increased soluble IL-5 receptor α in the airway after allergen challenge. J Immunol 169 (2002) 6452-6458
54. Liu L.Y., Sedgwick J.B., Bates M.E., Vrtis R.F., Gern J.E., Kita H., Jarjour N.N., Busse W.W., and Kelly E.A. Decreased expression of membrane IL-5 receptor α on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 169 (2002) 6459-6466
55. Gregory B., Kirchem A., Phipps S., Gevaert P., Pridgeon C., Rankin S.M., and Robinson D.S. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor α-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor α expression with loss of IL-5 responsiveness, but upregulate IL-3 receptor α expression. J Immunol 170 (2003) 5359-5366
56. Wilkins H.J., Crane M.M., Copeland K., and Williams W.V. Hypereosinophilic syndrome: an update. Am J Hematol 80 (2005) 148-157
57. Cogan E., Schandené L., Crusiaux A., Cochaux P., Velu T., and Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330 (1994) 535-538
58. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
59. Plötz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., Hein R., Smith T., Behrendt H., and Ring J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
60. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., Beck L.A., Boyce J.A., Filipovich A.H., Villanueva J.M., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
61. Rothenberg M.E., Klion A.D., Roufosse F.E., Emmanuel Kahn J., Weller P.F., Simon H.-U., Schwartz L.B., Rosenwasser L.J., Ring J., Griffin E.F., et al., Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228. In this study, the effect of mepolizumab on HES patients negative for Fip1-like 1-platelet-derived growth factor receptor α fusion gene (FIP1L1-PDGFRA) was evaluated by an international, randomized, double-blind, placebo-controlled trial. The authors showed that mepolizumab treatment enabled clinically significant reductions in corticosteroid dose, and often corticosteroid discontinuation, in HES patients without major safety concerns.
62. Koike M, Nakayama K, Furuya A, Shoji-Hosaka E, Iida A, Anazawa H, Shitara K, Takatsu K, Hanai M: Generation and characterization of POTELLIGENT anti-human IL-5Rα humanized monoclonal antibody, MED563. Eosinophil 2007, 5th Biennial Symposium, IES.
63. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278 (2003) 3466-3473. In this study, authors showed that anti-hIL-5Rα humanized IgG1 produced by rat hybridoma YB2/0 cell lines exerted more than 50-fold higher ADCC using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. These results indicate that low- or no-fucose antibody induces the most powerful ADCC activity, and provide important information to produce the effective therapeutic antibody.
64. Busse WW, Katial R, Leon F, Coyle AJ, Spitalny GL, Koike M, Wheeler A, Hanai N, White B: AMEDI-563, and anti-interleukin-5 receptor antibody, is well tolerated and induces reversible blood eosinopenia in mild asthma in a Phase I trial. MI-CP-158. Eosinophil 2007, 5th Biennial Symposium, IES.